© 2019 by Gastroenterology Associates of Central Georgia

  • Facebook Social Icon

Privacy Policy

478-464-2600

Abstracts

Dr. Sedghi Publications

‚Äč

ABSTRACTS (presented in meetings)

  1. S. Sedghi, JPMorgan, M. Doria, G. Urban, A. Keshavarizan. The role of oxygen free radicals in inflammatory colitis.  (American College of Gastroenterology, Oct. 1988) Am J Gastroenterol 1988:83:1050.
     

  2. A. Keshavaran, S. Sedghi, G. Risk, G. Urban, C. Wilson. The effect of acute ethanol on esophageal motility in cats: evidence for mediation. (American Motility Society, Oct. 1988) Gastroenterology 1988;95:875.
     

  3. A. Keshavarzian, S. Sedghi, D. Hecht, M. Doria. Mitomycin induced colitis in rats – a novel animal model. Clinical Research 1990;38:561A.
     

  4. S. Sedghi, E. Holmes, M. Doria, A. Keshavarzian. The role of intestinal permeability and reactive oxygen metabolities in mitomycin induced colitis. Clinical Research 1990;38:535A.
     

  5. N. Haroon, S. Sedghi, D. Winship, A. Keshavarzian. The effects of temperature on luminol enhanced chemiluminescence (CL) generated by the inflamed colonic mucosa. (FASEB April 1992) FASEB Journal 1992;6:A1057.
     

  6. M. Olyaee, S. Mobarhan, S. Sedghi, A. Grande, S. Sontag, A. Keshavarzian. Normal rectal mucosa generates increased levels of luminol enhanced chemiluminescence in patients with colonic neoplasia: A possible marker for colonic neoplasia (AGA May 1992). Gastroenterology 1992;102:A384.
     

  7. S. Kolli, R. Radvany, M. Klamut, S. Sedghi, A. Keshavarzian. Flow cytometric evaluation of peripheral T-lymphocyte subpopulation in patients with active inflammatory bowel disease. (AGA May 1992). Gastroenterology 1992;102:A647.
     

  8. S. Sedghi, M. Klamut, G. Urban, D. Fretland, A. Keshavarzian. Neutrophils are the major source of reactive oxygen metabolites (ROM) in colitis. AGA May 1992. Gastroenterology 1992;102:A693.
     

  9. S. Sedghi, C. Robinson, D. Fretland, D. Winship, A. Keshavarzian. Are eicosanoids the source of reactive oxygen metabolites (ROM) in experimental colitis? AGA May 1992. Gastroenterology 1992;102:A693.
     

  10. S. Sedghi, M. Klamut, G. Urban, M. Olyaww, D. Winship, A. Keshavarazian. Increased production of luminol chemiluminescence (CL) by the inflamed colonic mucosa: A sensitive index of disease activity in patients with ulcerative colitis (UC). AFCR May 1992.
     

  11. S. Sedghi, J.Z. Fields, G. Urban, M. Klamut, M. Durkin, D. Winship, A. Keshavarzian. Increased production of luminol enhanced chemiluminescence by the inflamed colonic mucosa in patients with ulcerative colitis- inhibition by indomethacin. AGA May 1993.
     

  12. S, Sedghi, N. Kazi, S. Steinbach, D. Eiznhamer, D. Winship, J.Z. Fields, A. Keshavarzian. Colonic factors that stimulate neutrophils (PMN) maybe involved in the pathophysiology of ulcerative colitis (UC). ACG 1993.
     

  13. S. Sedghi, A. Keshavarzian, M. Klamut, D. Eiznhamer, EJ Zarling. Increased breath ethane excretion is a non-invasive maker of disease activity in ulcerative colitis (UC). ACG 1993. Amer J Gastroenterology 1993;88:1583
     

  14. S. Sedghi, N. Kazi, S. Steinbach, D. Eiznhamer, D. Winship, J.Z. Fields, A Keshavarzian. Colonic factors that stimulate neutrophils (PMN) maybe involved in the pathophysiology of ulcerative colitis. (ACG New York 1993). Amer J Gastroenterology 1993;88:1583.
     

  15. S. Sedghi, N. Kazi, M. Doria, S. Steinbach, D. Eiznhamer, J. Z. Fields, A. Keshavarzian. Charcoal enema attenuates colonic inflammation induced in rats by acetic acid (HOA2); possible pathogenic role in luminal factors in ulcerative colitis (UC). 1993 AGA.
     

  16. S. Sedghi, N. Kazi, J.Z. Fields, D. Eiznhamer, V. Kottapalli, D. Winship, A. Keshavarzian. Midulation of neutrophil function by novel colonic factors: possible role in the pathophysiology of ulcerative colitis. 1993 AGA.
     

  17. A. Keshavarzian, T. Frommel, S. Sedghi, N. Kazi, D. Eiznhamer, J.Z. Fields. Midulatory role of colonic factors in homeostasis of reactive oxygen species (ROS) in ulcerative colitis (UC). World Congress of Gastroenterology 1994. October 1994
     

  18. V. Kottapalli, J.Z. Fields, s. Sedghi, D. Eizhamer, D. Winship, A. Keshavarzian. The effect of novel colonic factors in the pathophysiology of ulcerative colitis. ACG 1994, American Journal of Gastroenterology 1994 89(9):313.
     

  19. N. Kazi, J.Z. Fields, S. Sedghi, D. Eiznhamer, D. Winship, A. Keshavarzian. Pathophysiology of ulcerative colitis: possible role for novel colonic factors that modulate neutrophil function. AGA 1995 (submitted)
     

  20. R. Chadalavada, E. Lin, S. Sedghi, C. Dan Smith. Comparative results in endoluminal gastroplasty and laparoscopic antiflux surgery for the treatment of GERD. Society of American Gastrointestinal Endoscopic Surgeons. Los Angeles 2003
     

  21. S. Sedghi, L. Keefer, A. Keshavarzian, E. Sotil, E. Mutlu. Hostility in Gastrointestinal Patients Presenting to a Tertiary Care Center. AGA (submitted 2005).
     

  22. S. Sedghi, E. Lin, L. Khaitan, C. Dan Smith,. Objective Improvements Following Full-Thickness Gastric Cardia Plication for Complicated Gerd. Society of American Gastrointestinal Endoscopic Surgeons. (2005).
     

  23. R. Rahimi, L. Keefer, S. Sedghi, e. Mutlu, A. Keshavarzian. The impact of negative affectivity & conscientiousness on quality of life & symptom severity in patients with inflammatory bowel disease. DDW 2006
     

  24. G. Swanson, L.Keefer, S. Sedghi, A. Keshavarzian. The effect of normal alcohol consumption in inactive inflammatory bowel disease. DDW 2006
     

  25. S. Sedghi, R. Pruitt, A. Rosen. “Twice_daily Balsalazide Tablets Improve Patient Quality of Life After 2 and 8 weeks of Treatment:
    Results of a Phase 3, randomized, Double-blind, Placebo-Controlled, Multicenter Study”. DDW 2008 Abstract #441760
     

  26. S. Sedghi, R. Pruitt, A. Rosen. “Safety and Tolerability of Twice- Daily Balsalazide Tablets: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study”. DDW 2008 Abstract # 443054
     

  27. S. Sedghi, L. Harris. “Outcome of Difficult Patients with Severe Gastroesophageal Reflux Disease Treated by Endoscopic Gastroplication”. (2008)
     

  28. S. Sedghi, GL Gordon, R. Pruitt, M. Ringold, K. Merchant, A. Shaw, J. Yuan, E. Bortey, W. Forbes. “Once-Daily 1.5-g Granulated Mesalamine is Effective and Safe in Maintenance of Remission in Mild-to-Moderate Ulcerative Colitis.” Poster GMCC-009 ACG Annual Meeting October 5, 2008
     

  29. G Lichtenstein, GL fordon, S Zakko, U Murthy, S Sedghi, R Pruitt. J Yuan, K Merchant, A Shaw. A Low Incidence Of UC-Related Adverse Events Is Maintained in the Long Term Following Treatment with Mesalamine Granules(1.5 MG) QD in Patients Previously Treated With Corticosteroids. Draft, 25 June 2008 Long-Term Symptoms in Corticosteroid Subpopulation Abstract (ACG)
     

  30. AA. Rosen, S. Sedghi, RD. Shepard, S. Mareya, S. Huang, A. Shaw, WP. Forbes. “Twice-Daily Balsalazide Tablets Improve Patient Quality of Life After 2, 6, or 8 Weeks of Treatment”. Results of Two Phase 3, Randomized, Double-Blind Multicenter Studies. DDW 2009 (control id # 596587)
     

  31. AA. Rosen, S. Sedghi, RD. Shepard, S. Mareya, S. Huang, A. Shaw, WP. Forbes. “Safety & Tolerability of Twice-Daily Balsalazide Tablets: Results From 2 Randomized, Double-Blind, Multicenter, Phase 3 Studies and 1 Open-Label, Multicenter, Phase 3 Study. DDW 2009 (control id # 596147)
     

  32. AA. Rosen, S. Sedghi, RD. Shepard, S. Mareya, S. Huang, A. Shaw, WP. Forbes. “Long-term Safety of Once-Daily 1.5-g    Mesalamine Granules in Patients in Remission from Ulcerative Colitis.  DDW 2009 (control id # 596758)
     

  33. AA. Rosen, S. Sedghi. RD. Shepard, S. Mareya, S. Huang, A. Shaw, WP. Forbes. “Once-Daily Mesalamine Granules      Effectively Maintain Remission from Ulcerative Colitis: Data from 2 Phase 3 Trials. DDW 2009 (control id # 596772)
     

  34. Nathan Bass, Arun Sanyal, Fred Poordad, Muhammad Y Sheikh, Kevin D Mullen, Samuel Sigal, Todd Frederick, Robert Brown,BalRaj Bhandari, Shahriar Sedghi, Kunal Merchant, Shirley Huang, Audrey Shaw, Enoch Bortey, William P Forbes. “RFHE3001” AASLD abstract- Ammonia data. Rifaximin Decreases Venous Ammonia Concentrations’ and Time-Weighted Average Ammonia Concentrations Correlate with Overt Hepatic Encephalopathy (HE) as Assessed by Conn Score in a 6-Month Study. June 04, 2009
     

  35. G Lichtenstein, GL Gordon, S Zakko, U Murthy; S Sedghi, R  Pruitt, J Yuan, K Merchant, A Shaw, E Bortey, WP Forbes. “Effect Of Prognostic Factors on Maintenance of Remission From Ulcerative Colitis in Patients Treated With Once-Daily Mesalamine Granules (1.5g). Draft June 18, 2009 (ACG)
     

  36. Remo Panaccione, William Sandborn, Glenn L. Gordon, Scott Lee, Alan Safdi, Shahriar Sedghi, Brian Feagan, Stephen Hanauer, Ashish Kumar, Roberto Carcereri. Briakinumab (Anti-interleukin 12/23p40, ABT874) for Treatment of Crohn’s Disease (CD) 2010 ACG Abstracts
     

  37. N Bass, A Sanyal, F Poordad, M Sheikh, K Mullen, S Sigal, T Fredrick, R Brown, Jr., B Bhandari, S Sedghi, K Merchant,  S Huang, A Shaw, E Bortey, W Forbes. EASL 2010 Abstract. Rifaximin Decreases Venous Ammonia Concentrations and Time-Weighted Average Ammonia Concentrations Correlate with Overt Hepatic Encephalopathy (HE) as Assessed by Conn Score in a 6-Month Study.
     

  38. Ellen J. Scherl, MD, Rone E. Pruitt, MD, Shahriar Sedghi, MD, Andrew C. Barrett, PhD, Enoch Bortey, PhD, Craig Paterson, MD, William P. Forbes, PharmD. Long-Term Safety and Tolerability of Twice-Daily Balsalazide Disodium Tablets in Patients With Ulcerative Colitis. Poster Number P1045 ACG Annual Meeting October 14, 2013
     

  39. Chodhary, Mudit; Hang, Minh; Keshavarizian, Ali; Sedghi Shahriar. “Short Term Relief of Rectal Pain with Diazepam Cream: A Novel New Approach (submitted 2013 DDW)
     

  40. Keck, Carson; Chowdhary, Mudit; Varn, Matt; Hang, Minh; Keshavarzian, Ali; Sedghi, Shahriar.  “Sessile Serrated Polyp Detection Rate in a Large Community Practice as a Potential Quality Indicator for Colonscopy” (submitted 2013 DDW)

MANUSCRIPTS

  1. A. Keshavarzian, G. Morgan, S. Sedghi, J.H. Gordon, M. Doria. Role of reactive oxygen metabolites in experimental colitis. GUT 1990;31:786-790.
     

  2. A.Keshavarzian, G. Urban, S. Sedghi, C. Sweeney, C. Wilson. The effect of acute ethanol on esophageal motility. Alcoholism, Clinical and Experimental Research 1991;15:116-121.
     

  3. A. Keshavarzian, S. Sedghi, J. Kanofsky, T. List, C. Robinson, C. Ibrahim, D. Winship. Excessive production of reactive oxygen metabolites by inflamed colon: Analysis by chemiluminescence probe. Gastroenterology 1992;103:177-185.
     

  4. A.Keshavarzian, M. Doria, S. Sedghi, J. Kanofsky, D. Hecht, E. Holmes, C. Ibrahim, T. List, T. Gaginella, S. Parveen. Mitomycin-C induced colitis in rats- a new animal model of acute colonic inflammation implicating reactive oxygen species. Journal of Laboratory and Clinical Medicine 1992;120:779-791.
     

  5. S. Sedghi, M. Klamut, J.Z. Fields, G. Urban, M. Durkin, D. Winship, D. Fretland, M. Olyaee, A. Keshavarzian. Increased production of luminol enhanced chemiluminescence by the inflamed colonic mucosa in patients with ulcerative colitis. GUT 1993; 3(4):89-94.
     

  6. E. Zarling, S. Sedghi,. New therapies for inflammatory Bowel Disease. Hospital formulary. May 1993.
     

  7. N. Kazi, J.Z. Fields, S. Sedghi, L. Tierney, St, Steinbach, D. Winship, A. Keshavarzian. Modulation of neutrophil function by novel colonic factors: possible role in the pathophysiology of ulcerative colitis. GUT 1994
     

  8. S. Sedghi, A. Keshavarzian, MK Klamut, D. Eiznhamer, EJ Zarling. Breath ethane is a marker of lipid peroxidation in acute ulcerative colitis. American Journal of Gastroenterology 89(12):2217-2221, 1994
     

  9. J. Lane, S. Sedghi, M. Ajjan. GI bleeding from duodenal Diverticula. American Journal of Gastroenterology 96(9):2799,2001
     

  10. R. Chadalavada, DK Brown, AN Walker, S. Sedghi. Cronkhite-Candia Syndrome: Substained Remission After Corticosteroid Treatment. American Journal of Gastroenterology 98(6)1444-1446,2003.
     

  11. R. Chadalavada, E. Lin, V. Swafford, S. Sedghi, CD Smith. Comparative results of endoluminal gastroplasty and laparoscopic antireflux surgery for the treatment of GERD. Surg Endosc. 2004 Fec;18(2)261-5. Epub 2003 Dec 29. PMID: 14691698.
     

  12. Z. Ranjbaran, L. Keefer, A. Farhadi, A. Stepanski, S. Sedghi, A. Keshavarzian. The impact of sleep disturbance in inflammatory bowel disease. Journal of Gastro and Hep, 2006.
     

  13. D. Benjamin Christie III, William Douglas Luke,BS, Shahriar Sedghi. Ingested foreign-body retrieval: A novel Nre method. Gastrointestinal Endoscopy. 2007;Volume 65 No. 1: page 169-170.
     

  14. Lichtenstein, Gary; Zakko, Salam; Gordon, Glenn; Murthy, Uma; Sedghi, Shahriar; Pruitt, Ron; Merchant, Kunal; Bortey, Enoch; Forbes, William. APT 5142: Mesalamine granules 1.5-g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: A pooled analysis from two randomized controlled trials. Alimentary Pharmacology & Therapeutics, Volume 36, Issue 2, pages 126-134, July 2012
     

  15. 15. R Pannaccione, W Sandborn, G Gordon, S Lee, A Safdi, S Sedghi, B Feagan, S Hanauer, W Reinisch, J Valentine, B Huang, R Carcereri. Manuscript: Briakinumab for Treatment of Crohn’s Disease: results of a Randomized Trial (M10-222). Gastroenterology (In Press).
     

RESEARCH PROJECTS

  1. NDO Surgical Inc. Endoscopic Full-Thickness Gastroplication Outcomes in Normal and High Risk Patients (study completed)
     

  2. Salix Pharmaceutical Inc. A multi-center, randomized, double-blind, placebo-controlled trial to evaluate the use of mesalamine pellet formulation 1.5G QD to maintain remission from mild to moderate ulcerative colitis. (study completed)
     

  3. Salix Pharmaceutical Inc. A multi-center, open-label, treatment extension trial to evaluate the long-term safety and tolerability of mesalamine pellet formulation 1.5G QD in subjects in remission from mild to moderate ulcerative colitis. (study completed)
     

  4. Salix Pharmaceutical Inc. A multi-center, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of a new tablet formulation and dosing regimen of balsalazide disodium 3.3G BID versus placebo in mildly to moderately active ulcerative colitis. (study completed)
     

  5. Novartis Pharmaceuticals Corporation. A 6 week, randomized. double-blind, placebo-controlled, multi center study to assess   the efficacy and safety of oral trgaserod (6mg BID) and placebo in female patients with dyspepsia. (study completed)
     

  6. Protein Design Labs, Inc. A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative   Colitis (study completed)
     

  7. Protein Design Labs, Inc. A Randomized, Double-blind, Multicenter Study of Visilizumb versus Placebo in Subjects with Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study (study completed)
     

  8. Protein Design Labs, Inc. An Observational Follow-up Study For Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis (study completed)
     

  9. Abbott Laboratories, A Multicenter, Open-Label Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Patients with Moderate to Severe Crohn’s Disease with Previous Exposure to Inflaximab. (study completed)
     

  10. Salix Pharmaceutical Inc. A Multicenter, Open-Label Trial to  Evaluate the Long-Term Safety and Tolerability of a New Balsalazide Disodium Tablet Formulation in Patients with Ulcerative Colitis (study completed)
     

  11. Salix Pharmaceutical Inc. A Multicenter Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Rifaximin 550mg BID for 6 months in Preventing Hepatic Encephalopathy (study completed)
     

  12. Salix Pharmaceutical Inc. A Multicenter Open-Label Trial to Evaluate the Long Term Safety and Tolerability of Rifaximin 550mg BID in Subjects with a History of Hepatic Encephalopathy (study completed)
     

  13. Salix Pharmaceutical Inc. An Open-Label Sub-Study to Evaluate the Pharmacokinetics of Rifaximin during Long Term Treatment in Subjects with Impaired Liver Function (study completed)
     

  14. Salix Pharmaceutical Inc. A Multicenter, Randomized, Double-Blind, Actively controlled Parallel-Group Trial to Evaluate The Safety and Efficacy of a New Tablet Formulation and Dosing Regimen of Balsalazide Disodium 3.3g BID versus Mesalamine (5-ASA) as Asacol 0.8g TID in Mildly to Moderately Active Ulcerative Colitis (study completed)
     

  15. Shire A phase IV, Multicenter Open Label Study to assess clinical recurrence related to compliance with treatment with MMX Mesalamine 2.4g/day given once daily for the maintenance of quiescent ulcerative colitis (study completed)
     

  16. Abbott Laboratories, A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects with Moderately to Severely Active Ulcerative Colitis (study completed)
     

  17. Eisai, A Randomized Double-Blind Parallel Study of Rabeprazole Extended Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD) (study completed)
     

  18. Eisai, A Randomized Double-Blind Parallel Study of Rabeprazole Extended Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD) (study completed)
     

  19. Eisai, A Randomized Double-Blind Parallel Study of Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD) (study completed)
     

  20. Shire, A Phase III, Randomized, Double-Blind, Dose- Response Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 versus Placebo over 104 weeks in the Prevention of Recurrence of Diverticulitis (study completed)
     

  21. Abbott Laboratories, A Phase 2B, Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Ranging Study Comparing to Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 versus  Placebo in Subjects with Moderately to Severely Active Crohn’s Disease (study completed)
     

  22. Abbott Laboratories, A Multi-Center, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety of Repeated Administration of Adalimumab in Subjects with Ulcerative Colitis (study completed)
     

  23. Abbott Laboratories, A 5-Year Non-Interventional Registry Study of  HUMIRA® (Adalimumab) in Subjects with Moderately to Severely Active Crohn’s Disease (CD) (study completed)
     

  24. Millennium Pharmaceuticals, Inc., A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients with Moderate to Severe Ulcerative Colitis (study completed)
     

  25. Millennium Pharmaceuticals, Inc., A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients with Moderate to Severe Crohn’s Disease
     

  26. Centocor, Kendle International, Inc., A Phase 2b, Multicenter, Randomized, Double-blind, Placebo controlled, Parallel group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects with Moderately to Severely Active Crohn’s Disease Previously Treated with TNF Agonist Therapy
     

  27. Roche, Prospective, Observational Study on predictors of early on-treatment  response and sustained virological response in a cohort of treatment naïve HCV-infected patients treated with  pegylated interferons
     

  28. Salix Pharmaceuticals, Inc., A phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin 550 mg TID in the Treatment of Subjects with Non-Constipation Irritable Bowel Syndrome (study completed)
     

  29. Secure, A Non-Interventional Long-Term Post-Marketing  Registry of Patients Treated with Certolizumab Pegol (Cimzia ®) for Crohn’s Disease
     

  30. Abbive, A Randomized, Open-Label, Multicenter Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics, of ABT-450 with Ritonavir (ABT-450/r) in combination with ABT-267 and/or ABT-333 With and Without Ribavirin (RBV) for 8, 12 or 24 Weeks in Treatment-Naïve and Null Responder Subjects with Genotype 1 Chronic Hepatitis C Virus Infection. (study completed)
     

  31. Tsumura, A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study of Daikenchuto (TU-100) in Subjects with Moderate Crohn’s Disease. (study completed)
     

  32. Janssen, A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely Active Crohns’s Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy.
     

  33. Janssen, A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely Active Crohns’s Disease.
     

  34. Janssen, Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (infliximab) and Placebo in the Prevention of Recurrence in Crohn’s Disease patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence.
     

  35. Salix, A Multicenter, Randomized, Open-Label, Active-Controlled, Trial To Evaluate The Safety and Efficacy of Rifaximin 550mg With and Without Lactulose in Subjects with A History of Recurrent Overt Hepatic Encephalopathy.
     

  36. Pfizer, A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Investigate The Safety and Efficacy of Multistem (PF-05285401) In Subjects With Moderate To Severe Ulcerative Colitis. (study completed)
     

  37. Pfizer, A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Centre Study To Investigate The Safety and Efficacy of CP-690,550 For Induction Therapy in Subjects with Moderate to Severe Crohn’s Disease.
     

  38. Pfizer, A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral CP-690,550 As An Induction Therapy In Subjects With Moderate To Severe Ulcerative Colitis.
     

  39. Salix, A Study To Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 Mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D). (study completed)
     

  40. Salix A Phase 4 Randomized, Active Comparator, Open  Label, Multicenter Study To Assess The Safety and Efficacy of Osmoprep Tablets versus Halflytely and Bisacodyl Tablet Bowel Prep Kit for Colon Cleansing.
     

  41. Prometheus, A Study to Assess the Association of Clinical Outcome with Serum Drug Concentration Levels and Anti-Drug Antibody in Moderately to Severely Active Crohn’s Disease patients Treated With Adalimumab. (study completed)
     

  42. AstraZeneca, A Phase 2a Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn’s Disease Who Have Failed or Are Intolerant to Anti-tumor Necrosis factor-alpha Therapy.
     

  43. Furiex, A Randomized, Double-Blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy Safety and Tolerability JNJ-27018966 in the Treatment of Patients With-Predominant Irritable Bowel Syndrome. (study completed)
     

  44. Salix, A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess The Efficacy and Safety of Budesonide Foam (2mg/25ml BID for 2 weeks, Followed by 2 mg/25ml QD for 4 weeks) versus Placebo in Subjects With Active Mild To Moderate ulcerative Proctitis or Proctosigmoiditis. (study completed)
     

  45. RUSH ORA 02093006 NIH NCCAM 4-21 #AT 001628-10A2-Dietary Treatment of Crohn’s Disease. (study completed)
     

  46. Dr. Falk, Double-blind, Dose-Response, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Phase III Clincial Study on the Efficacy and Tolerability of Mesalazine Granules Vs. Placebo for the Prevention of Recurrence of Diverticulitis. (study completed)
     

  47. Hutchison Medi Pharma-A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Trial of HMPL-004 in Patients with Mild To Moderate Active Ulcerative Colitis.
     

  48. Abbvie-A Multicenter Study Evaluating a Practical IndEx  Score for Subjects with Crohn’s Disease Assessing the Absence of Mucosal UICeraTion (Predict)
     

  49. Salix-A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study To Assess The Efficacy And Safety Of Rifaximin Soluble Solid Dispersion (SSD) Tablets For the Prevention of Complications In Subjects With Early Decompensated Liver Cirrhosis
     

  50. SK Life Science-A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week, Dose-Ramge-Finding Trial of 5 and 20 mg Capsules of YKP10811 Administered Once Daily at Doses of 5, 10, or 30mg to Subjects with Chronic Idiopathic Constipation.
     

  51. Abbvie-A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection.
     

  52. Roche-Phase III, Double Blind, Placebo-Controlled, Multicenter Study Of The Efficacy and Safety of Etrolizumab During Induction and Maintenance In Patients With Moderate To Severe Activee Ulcerative Colitis Who Are Refractory To or Intolerant of TNF Inhibitors.
     

  53. Abbvie-A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Two Adalimumab Induction Regimens in Subjects with Moderately to Severely Active Crohn’s Disease and Evidence of Mucosal Ulceration.
     

  54. Abbvie-A Double-Blind, Randomized, Multicenter Study of higher Versus Standard Adalimumab Dosing Regimens For Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis.
     

  55. Luitpold Pharmaceuticals-A Multi-Center, Randomized, Open-Label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer (Ferric Carboxymaltose) vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficiency Anemia (IDA) secondary to Inflammatory Bowel Disease (IBD).
     

  56. Abbvie- An Open-Label Study to Evaluate the Safety Antiviral Activity and Pharmacokinetics of Direct –Acting Antiviral Agent (DAA) Treatment in Combination with Peginterferon a-2a and Ribavirin (pegIFN/RBV) in Chronic Hepatitis C Virus (HCV) Infected Subjects Who Have Experienced Virologic Failure in a Previous Abbott DAA Combination Study.